Naoki Kaneko Selected Research

Therapeutics

5/2024	Recent Translational Research Models of Intracranial Atherosclerotic Disease.
12/2022	Impact of ARUBA trial on trends and outcomes in symptomatic non-ruptured brain AVMs: A national sample analysis.
1/2021	Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2.
1/2020	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis.
1/2019	Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
1/2018	High performance plasma amyloid-β biomarkers for Alzheimer's disease.
4/2014	Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
9/2011	YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
8/2011	Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
6/2011	Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoki Kaneko Research Topics

Disease

22	Neoplasms (Cancer) 01/2023 - 04/2009
9	Aneurysm (Aneurysms) 05/2023 - 07/2017
6	Ischemic Stroke 10/2023 - 03/2019
5	Intracranial Aneurysm (Cerebral Aneurysm) 03/2023 - 08/2016
4	Stroke (Strokes) 05/2024 - 01/2021
4	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2014
4	Squamous Cell Carcinoma of Head and Neck 01/2023 - 05/2015
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 06/2011
4	Lymphoma (Lymphomas) 06/2011 - 03/2006
3	Immunoglobulin G4-Related Disease 01/2022 - 01/2020
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2018 - 06/2011
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017 - 06/2016
3	Ischemia 10/2014 - 01/2012
3	Body Weight (Weight, Body) 04/2014 - 08/2011
2	Inflammation (Inflammations) 01/2023 - 10/2021
2	Cognitive Dysfunction 12/2022 - 01/2020
2	Pathologic Constriction (Stenosis) 10/2022 - 01/2021
2	Fibrosis (Cirrhosis) 01/2022 - 10/2021
2	COVID-19 01/2022 - 01/2021
2	Kimura Disease 01/2022 - 12/2019
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2019 - 10/2017
2	Breast Neoplasms (Breast Cancer) 09/2018 - 09/2011
2	Renal Cell Carcinoma (Grawitz Tumor) 05/2013 - 08/2008
2	Triple Negative Breast Neoplasms 01/2013 - 09/2011
2	Cardiac Arrhythmias (Arrythmia) 01/2011 - 01/2011
2	Premature Cardiac Complexes (Extrasystoles) 01/2011 - 01/2011
2	Atrioventricular Block 01/2011 - 01/2011
1	Atherosclerosis 05/2024
1	Oral Lichen Planus 11/2023
1	Tissue Adhesions 10/2023
1	Hemorrhage 10/2023
1	Fatigue 10/2023
1	Wounds and Injuries (Trauma) 10/2023
1	Varicose Veins (Varicose Vein) 01/2023
1	Hypotension (Low Blood Pressure) 01/2023
1	Autoimmune Diseases (Autoimmune Disease) 01/2023
1	Glioma (Gliomas) 01/2023
1	Epidural Abscess 12/2022
1	Obesity 12/2022
1	Arteriovenous Malformations (Arteriovenous Malformation) 12/2022
1	Amyloidosis 01/2022
1	Respiratory Sounds (Crackle) 01/2022

Drug/Important Bio-Agent (IBA)

10	SurvivinIBA 12/2018 - 06/2011
10	sepantroniumIBA 09/2018 - 06/2011
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2006
5	Amyloid (Amyloid Fibrils)IBA 01/2023 - 01/2014
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2018
3	CytokinesIBA 01/2022 - 05/2015
3	Rituximab (Mabthera)FDA Link 01/2020 - 10/2012
2	ChemokinesIBA 12/2022 - 01/2020
2	Biocompatible Materials (Biomaterials)IBA 09/2022 - 01/2022
2	Immunoglobulin E (IgE)IBA 01/2022 - 12/2019
2	EnzymesIBA 01/2020 - 05/2013
2	naquotinibIBA 01/2020 - 01/2019
2	gilteritinibIBA 04/2019 - 10/2017
2	Neuroprotective AgentsIBA 12/2018 - 01/2012
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2016 - 06/2016
2	Parathyroid Hormone-Related ProteinIBA 07/2016 - 06/2016
2	Hormones (Hormone)IBA 06/2016 - 01/2012
2	Tumor Biomarkers (Tumor Markers)IBA 05/2013 - 05/2011
2	Galectin 1 (LGALS1)IBA 05/2013 - 05/2011
2	Docetaxel (Taxotere)FDA Link 01/2013 - 08/2011
2	Sotalol (Sotalol Hydrochloride)FDA LinkGeneric 01/2011 - 01/2011
2	Histidine (L-Histidine)FDA Link 06/2009 - 05/2009
2	Antigen Receptors (Antigen Receptor)IBA 05/2009 - 04/2009
1	Cathepsin KIBA 11/2023
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2023
1	catechol (pyrocatechol)IBA 10/2023
1	PyrogallolIBA 10/2023
1	Hemostatics (Antihemorrhagics)IBA 10/2023
1	Contrast MediaIBA 01/2023
1	AcidsIBA 01/2023
1	Vasoconstrictor AgentsIBA 01/2023
1	Sclerosing Solutions (Sclerosing Agents)IBA 01/2023
1	CatecholaminesIBA 01/2023
1	Immunoglobulin D (IgD)IBA 01/2023
1	Arginine Vasopressin (Argipressin)IBA 01/2023
1	AntibodiesIBA 01/2023
1	InterleukinsIBA 12/2022
1	HydrogelsIBA 09/2022
1	Muramidase (Lysozyme)IBA 01/2022
1	DeodorantsIBA 01/2022
1	ChloridesIBA 01/2022
1	Amyloid beta-PeptidesIBA 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Interleukin-13IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	SilicatesIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022

Therapy/Procedure

10	Therapeutics 05/2024 - 06/2011
6	Thrombectomy 10/2023 - 03/2019
6	Stents 08/2023 - 03/2019
4	Catheters 05/2023 - 01/2022
4	Oral Administration 01/2023 - 01/2011
4	Drug Therapy (Chemotherapy) 04/2019 - 08/2008
3	Radiotherapy 12/2022 - 08/2008
2	Craniotomy 01/2023 - 12/2022
2	Punctures 01/2022 - 01/2021
2	Surgical Instruments (Clip) 10/2018 - 07/2017
1	Immunotherapy 01/2023